Skip to main content
SpringerLink
Log in

Zytostatische Chemotherapie

  • Chapter
Book cover Die Onkologie

  • 344 Accesses

Zusammenfassung

Die zytostatische Chemotherapie hat in den letzten Jahrzehnten eine rasante Entwicklung durchgemacht. Sie hat zu entscheidenden Fortschritten in der Behandlung hämatologischer Neoplasien geführt und ist auch bei etwa der Hälfte der soliden Tumoren effektiv.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adjei AA (2000) Signal transduction pathway targets for anticancer drug discovery. Curr Pharm Des 6: 361–78

    Article  PubMed  CAS  Google Scholar 

  • Advani R, Visani G, Milligan D et al.(1999)Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone,etoposide,and cytarabine (PSC-MEC). Adv Exp Med Biol 457: 47–56

    Article  Google Scholar 

  • Ambudkar SV, Dey S, Hrycyna CA, Rämachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398

    Article  PubMed  CAS  Google Scholar 

  • Barreff MW (1998) Chemoradiation for rectal cancer: current methods. Semin Surg Oncol 15: 114–119

    Article  Google Scholar 

  • Baselga J, Averbuch SD (2000) ZD1839 (“Iressa”) as an anticancer agent. Drugs 60 [Suppl 1]: 33; discussion 41–42

    Google Scholar 

  • Belani CP, Ramanathan RK (1 998) Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents. Chest 113 [Suppl 11: 535–60S

    Google Scholar 

  • Berger T, Malayeri R, Doppelbauer A, Krajnik G, Huber H, Auff E, Pirker R (1997) Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 33: 1393–1399

    Article  PubMed  CAS  Google Scholar 

  • Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH, Drinkard L (1997) Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res 3: 2633–2637

    PubMed  CAS  Google Scholar 

  • Borsi JD, Sagen E, Romslo I, Moe PJ (1990) Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice. Pediatr Hematol Oncol 7: 347–363

    Article  PubMed  CAS  Google Scholar 

  • Bunn PA Jr, Crowley J, Kelly K et al. (1995) Chemoradiotherapy with or without granulocytemacrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase Ill randomized study of the Southwest Oncology Group. J Clin Oncol 13: 1632–1641

    PubMed  Google Scholar 

  • Calvert AH, Newell DR, Gumbrell LA et al. (1989) Carboplatin dosage: prospective evaluation of a simple formula based an renal function. J Clin Oncol 7: 1748–1756

    PubMed  CAS  Google Scholar 

  • Carew JF, Shah JP (1998) Advances in multimodality therapy for laryngeal cancer. CA Cancer J Clin 48: 211–228

    Article  PubMed  CAS  Google Scholar 

  • Charbit A, Malaise EP,Tubiana M (1971) Relationship between the pathological nature and the growth rate of human tumors. Eur J Cancer 7: 307

    CAS  Google Scholar 

  • Clayman GL (2000) The current status of gene therapy. Semin Oncol 27 [Suppl 8]: 39–43

    PubMed  CAS  Google Scholar 

  • Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41

    Article  PubMed  CAS  Google Scholar 

  • Coley HM,Twentyman PR, Workman P (1990) 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. EurJ Cancer 26: 665–667

    Google Scholar 

  • Conley BA,Van Echo DA (1992) Antineoplastic drug development.ln: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, pp 15–21

    Google Scholar 

  • Cooper MR, Cooper MR (1991) Principles of medical oncology.ln:Holleb AI, Fink DJ, Murphy GP ( 1991 ) American Cancer Society Textbook of Oncology.The American Cancer Society, Atlanta

    Google Scholar 

  • Covelli A (1999) Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 10 [Supp16]: 53–59

    Article  PubMed  Google Scholar 

  • Dalgleish AG (2000) Cancer vaccines. Br J Cancer 82: 1619–1624

    Article  PubMed  CAS  Google Scholar 

  • Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ (2000) Cisplatin resist-ance and oncogenes–a review. Anticancer Drugs 11: 225–236

    Article  PubMed  CAS  Google Scholar 

  • Dodion P, Kenis Y, Staquet M (1986) Phase I trials of single agents in adult solid tumours: preclinical and clinical aspects. Drugs Exp Clin Res 12: 23–30

    PubMed  CAS  Google Scholar 

  • Eberhardt W, Wilke H, Stamatis G et al. (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based an hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer:mature results of a phase Il trial. J Clin Oncol 16: 622–634

    PubMed  CAS  Google Scholar 

  • Eberhardt W, Stamatis G, Stuschke M et al. (1999) Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial. Br J Cancer 81: 1206–1212

    Article  PubMed  CAS  Google Scholar 

  • Edler L (1990) Statistical requirements of phase I studies. Onkologie 13: 90–95

    Article  PubMed  CAS  Google Scholar 

  • Eisenhauer EA, O’Dwyer Pi, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18: 684–692

    PubMed  CAS  Google Scholar 

  • EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in phase 1 clinical trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23: 1083–1087

    Article  Google Scholar 

  • Feldman AL, Libutti SK (2000) Progress in antiangiogenic gene therapy of cancer. Cancer 89: 1181–1194

    Article  PubMed  CAS  Google Scholar 

  • Filipits M,Suchomel RW,Zöchbauer S, Malayeti R,Pirker R (1996) Clinical relevance of drug resistance genes in malignant diseases. Leukemia 10: S10 - S17

    Google Scholar 

  • Filipits M, Pohl G, StranzlTet al. (1998). Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91: 1508–1513

    PubMed  CAS  Google Scholar 

  • Filipits M, Drach J, Pohl G et aí. (1999) Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 5: 2426–2430

    PubMed  CAS  Google Scholar 

  • Filipits M, Jaeger U, Simonitsch I, Chizzali-Bonfadin C, Heinzl H, Pirker R (2000a) Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res 6: 3417–3423

    PubMed  CAS  Google Scholar 

  • Filipits M, Stranzl T, Pohl G et al. (2000b) Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 1 4: 68–76

    Article  Google Scholar 

  • Fuse E, Kobayashi S, Inaba M, Suzuki H, Sugiyama Y (1994) Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.) Natl Cancer Inst 86: 989–996

    CAS  Google Scholar 

  • Gokbuget N, Hoelzer D (1996) High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Ann Hematol 72: 194–201

    Article  PubMed  CAS  Google Scholar 

  • Gordon AN,Granai CO,Rose PG etal. (2000) Phase II studyof liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18: 3093–3100

    Google Scholar 

  • Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms ofcisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16–39

    PubMed  CAS  Google Scholar 

  • Graham MA,Workman P (1992)The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. Ann Oncol 3:339–347

    Google Scholar 

  • Gralla RJ, Osoba D, Kris M (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.) Clin Oncol 17: 2971–2994

    CAS  Google Scholar 

  • Green MC, Murray JL, Hortobagyi GN (2000) Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 26: 269–286

    Article  PubMed  CAS  Google Scholar 

  • Greene MH, Boice JD Jr, Greer BE, Blessing JA, Dembo AJ (1982) Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer:a study of five randomized clinical trials. N Engl J Med 307: 1416–1421

    Article  PubMed  CAS  Google Scholar 

  • Grem JL (2000) 5-Fluorouracil:forty-plus and still ticking.A review of its pre-clinical and clinical development. Invest New Drugs 18:299–313

    Google Scholar 

  • Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced eme-sis. N Engl J Med 329: 1790–1796

    Article  PubMed  CAS  Google Scholar 

  • Ham SJ, van der Graaf WT, Pras E, Molenaar WM, van den Berg E, Hoekstra HJ (1 998) Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. Cancer Treat Rev 24: 373–391

    Google Scholar 

  • Hensley ML, Schuchter LM, Lindley C et al. (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17: 3333–3355

    PubMed  CAS  Google Scholar 

  • Hochster H, Liebes L,Wadler Set aí. (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.J Natl Cancer Inst 84: 1725–1730

    CAS  Google Scholar 

  • Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ,Yang CP (1993) Taxol: mecha- nisms of action and resistance.) Natl Cancer Inst Monogr 15: 55–61

    Google Scholar 

  • Jelliffe RW (1971) Estimation of creatinine clearance when urine cannot be collected. Lancet 1: 975–976

    Article  PubMed  CAS  Google Scholar 

  • Kandioler-Eckersberger D, Kappel S, Mittlbock M et al. (1999) The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.) Thorac Cardiovasc Surg 117: 744–750

    CAS  Google Scholar 

  • Karakousis CP, Driscoll DL (1999) Treatment and local control of primary extremity soft tissue sarcomas.J Surg Onco171:155–161

    Google Scholar 

  • Kelsen DP (2000) Multimodality therapy of esophageal cancer:an update. Cancer J Sci Am 6 [Supp12]: 177–181

    Google Scholar 

  • Knox SJ, Meredith RF (2000) Clinical radioimmunotherapy. Semin Radiat Oncol 10: 73–93

    Article  PubMed  CAS  Google Scholar 

  • Krajnik G, Mohn-Staudner A, Thaler J et al. (2000) Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC):an AASLC phase II tri-al. Austrian Association for the Study of Lung Cancer. Ann Oncol 11: 993–998

    Article  PubMed  CAS  Google Scholar 

  • Kuss B, Cotter F (1999) Antisense–time to shoot the messenger. Ann Onco1 10: 495–503

    Article  CAS  Google Scholar 

  • La Quaglia MP (1998) Osteosarcoma.Specific tumor management and results. Chest Surg Clin N Am 8: 77–95

    PubMed  Google Scholar 

  • Lebwohl DE, Canetta R (1999) New developments in chemotherapy of advanced breast cancer. Ann Oncol 10 [Suppl 6]: 139–146

    Article  PubMed  Google Scholar 

  • Lehnert T (1999) Multimodal therapy for squamous carcinoma of the oesophagus. Br J Surg 86: 727–739

    Article  PubMed  CAS  Google Scholar 

  • Lerut T, Coosemans W, De Leyn P, Van Raemdonck D, Deneffe G, Decker G (1999) Treatment of esophageal carcinoma. Chest 116 [Suppl 6]: 4635–4655

    Google Scholar 

  • Lombardi F, Navarria P,Gandola L (1998)Theevolving role of radiation therapy in the optimal multimodality treatment of childhood cancer.Tumori 84:270–273

    Google Scholar 

  • Malayeri R, Filipits M, Suchomel RW, Zöchbauer S,Lechner K, Pirker R (1996) Multidrug resistance genes in leukemias and its reversal. Leukemia Lymphoma 23: 451–458

    Article  CAS  Google Scholar 

  • Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (mdrl) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586–592

    PubMed  CAS  Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214

    Article  PubMed  CAS  Google Scholar 

  • Ozer H, Armitage JO, Bennett CL et al. (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.) Clin Oncol 18: 3558–3585

    Google Scholar 

  • Pastan I, Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42: 277–286

    Article  PubMed  CAS  Google Scholar 

  • Pastan I (1997) Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta 1333: C1–6

    PubMed  CAS  Google Scholar 

  • Patterson W, Reams GP (1992) Renal toxicities of chemotherapy.Semin On-col 19: 521–528

    CAS  Google Scholar 

  • Perry MC (1992) Chemotherapeutic agents and hepatotoxicity.Semin On-col 19: 551–565

    CAS  Google Scholar 

  • Pirker R, FitzGerald DJ, Handton TC et al. (1985) Characterization of immunotoxins active against ovarian cancer cell lines. J Clin Invest 76: 1261–1267

    Article  PubMed  CAS  Google Scholar 

  • Pirker R, Keilhauer G, Raschack M, Lechner C; Ludwig H (1990) Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil.Int J Cancer 45: 916–919

    CAS  Google Scholar 

  • Pirker R, Wallner J, Geissler K et al. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712

    Article  PubMed  CAS  Google Scholar 

  • Pirker R, Malayeri R, Huber H (1999) Adjuvant and induction chemothera- py in non-small cell lung cancer. Ann Oncol 10 [Suppl 61: 71–76

    Article  Google Scholar 

  • Pirker R, Smith R (2002) Darbepoetin alfa: potential role in managing ane- mia in cancer patients. Expert Rev AnticancerTher 2: 377–384

    Article  CAS  Google Scholar 

  • Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6 [Suppl 6]: 7–13

    Article  PubMed  CAS  Google Scholar 

  • Prendergast GC (2000) Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 12: 166–173

    Article  PubMed  CAS  Google Scholar 

  • Ratain MJ, Schilsky RL, Conley BA, Egorin MJ (1990) Pharmacodynamics in cancer therapy.) Clin Oncol 8: 1739–1753

    CAS  Google Scholar 

  • RizzoJD,Lichtin AE,Woolf SH et al.,and the American Society of Clinical Oncology, American Society of Hematology (2002) Use of epoetin in pa-

    Google Scholar 

  • tients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083–4107

    Google Scholar 

  • Rosell R, Felip E (2000) Role of multimodality treatment for lung cancer. Semin Surg Oncol 18: 143–151

    Article  PubMed  CAS  Google Scholar 

  • Schiff P, Fant J, Horwitz S (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665

    Article  PubMed  CAS  Google Scholar 

  • Schwartz SA, Morgenstern B, Capizzi RL (1982) Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5,178Y murine Ieukemia.Cancer Res 42: 2191–2197

    CAS  Google Scholar 

  • Shackney SE, McCormack GW, Cuchural GJ (1978) Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 89: 107

    Article  PubMed  CAS  Google Scholar 

  • Silver RT, Young RC, Holland JF (1977) Some aspects of modern cancer chemotherapy. Am J Med 63: 772

    Article  PubMed  CAS  Google Scholar 

  • Steel GG (1967) Cell loss as a factor in the growth rate of human tumors. Eur J Cancer 3: 381

    Article  PubMed  CAS  Google Scholar 

  • Stevenson FK (1999) DNA vaccines against cancer:from genes to therapy. Ann Oncol 10: 1413

    Article  PubMed  CAS  Google Scholar 

  • Sugarbaker DJ, Norberto JJ (1998) Multimodality management of malignant pleural mesothelioma.Chest 113 [Suppl 1): 61S - 65S

    CAS  Google Scholar 

  • Swisher SG, Roth JA (2000) Gene therapy in lung cancer. Curr Oncol Rep 2: 64–70

    Article  PubMed  CAS  Google Scholar 

  • Tennant TR, Rinker-Schaeffer CW, Stadler WM (2000) Angiogenesis Inhibitors. Curr Oncol Rep 2: 11–16

    Article  PubMed  CAS  Google Scholar 

  • Therasse P,Arbuck SG, Eisenhauer EA et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.) Natl Cancer Inst 92: 205–216

    Article  CAS  Google Scholar 

  • Vansteenkiste J, Pirker R, Massuti B et al., and Aranesp 980297 Study Group (2002) Double-blind, placebo-controlled, randomized phase Ill trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211–1220

    Google Scholar 

  • Vidal Pocket (2000) Arzneimittelinformation VIDAL GmbH, 6020 Innsbruck, S 662–663

    Google Scholar 

  • Weill D, Mack M, Roth J, Swisher S, Proksch S, Merritt J, Nemunaitis J (2000) Adenoviralmediated p53 gene transfer to non-small cell lung cancer through endobronchial injection.Chest 118: 966–970

    CAS  Google Scholar 

  • Weiner LM (1999) Monoclonal antibody therapy of cancer. Semin Oncol 26 [Suppl 141: 43–51

    Google Scholar 

  • White AW, Almassy R, Calvert AH et al. (2000) Resistance-modifying agents. 9.(1) synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme Poly(ADP-ribose) polymerase.J Med Chem 43: 4084–4097

    Article  PubMed  CAS  Google Scholar 

  • Yarbro JW (1992) The scientific basis of cancer chemotherapy. In: Perry MC (ed) The chemotherapy source book.Williams & Wilkins, Baltimore, pp 2–14

    Google Scholar 

  • Yuen AR, Sikic BI (2000) Clinical studies of antisense therapy in cancer. Front Biosci 5: D588

    Article  PubMed  CAS  Google Scholar 

  • Zöchbauer-Müller S, Pirker R, Huber H (1999) Treatment of small cell lung cancer patients. Ann Oncol 10 [Supp16]: 83–91

    Article  PubMed  Google Scholar 

  • Zujewski J, Horak ID, Bol CJ et al. (2000) Phase I and pharmacokinetic study of famesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18: 927–941

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. Pirker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pirker, R. (2004). Zytostatische Chemotherapie. In: Die Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-06670-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-06670-6_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-06671-3

  • Online ISBN: 978-3-662-06670-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation